Edgar Filing: WEG KENNETH E - Form 4

WEG KENNE Form 4											
April 24, 2013 FORM	 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 box STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 20(b) of the Investment Company Act of 1040 									PROVAL 3235-0287	
Check this if no longer subject to Section 16. Form 4 or Form 5 obligations may contin <i>See</i> Instruct 1(b).									burden hou response	Estimated average burden hours per response 0.5	
(Print or Type Re	sponses)										
WEG KENNETH E Sym				2. Issuer Name and Ticker or Trading Symbol AVEO PHARMACEUTICALS INC [AVEO]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Month/			(Month/D	h/Day/Year) –				X_ Director 10% Owner Officer (give title Other (specify below) below)			
	(Street) 4. If Amendm Filed(Month/I				-			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 			
CAMBRIDG								Person			
	(State) 2. Transaction I (Month/Day/Ye	ar) Executio any	med	3. Transactio Code (Instr. 8) Code V	4. Securi n(A) or Di (D) (Instr. 3,	ties Ao spose	cquired d of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	f, or Beneficial 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of	
Common Stock	04/01/2013			A <u>(1)</u>	1,724	A	\$ 7.25	43,216	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: WEG KENNETH E - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Secur	ınt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owna Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
WEG KENNETH E C/O AVEO PHARMACEUTICALS, INC. 75 SIDNEY STREET CAMBRIDGE, MA 02139	X						
Signatures							
/s/ Joseph D. Vittiglio, attorney-in-fact	04/24/20	13					
**Signature of Reporting Person	Date						

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The transaction reported in this Form 4 was effected pursuant to the reporting person's election on December 5, 2012, in accordance with
 (1) a policy established by the board effective in 2013, to receive 100% of his quarterly installment of board fees in the form of unrestricted shares of AVEO common stock, issued under AVEO's 2010 Stock Incentive Plan, as amended.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.